866-997-4948(US-Canada Toll Free)

Published on : Jul 26, 2016

ALBANY, New York, July 26, 2016: Hematological malignancies affect the bone marrow, lymph nodes, and the blood. They comprise various forms of lymphoma, myeloma, and leukemia. Currently, the large hematological cancer pipeline is displaying a strong level of innovation. Unmet needs will continue to boost the hematological cancers market. However, the entry of new entrants will create new opportunities for biological products. As a result, innovative product development still remains attractive in the market. The shifts in reimbursement and regulatory policies will favor product innovation. These are some of the findings of a new report recently added by ResearchMoz.us to its vast database of research reports.   

The report, titled ‘Frontier Pharma: Hematological Cancers - Highly Innovative Pipeline Continues Trend towards Targeted, Patient-Specific Therapies,’ assesses changing trends and innovations taking place in the hematological cancer pipeline. The hematological cancer pipeline is one of the most innovative in the market, with almost 463 products. The hematological cancer pipeline accounts for 45.3% of the total cancer pipeline. The research finds that lymphomas are more commonly found than myeloma and leukemia. 

The 73-page publication defines hematological cancer and then analyzes various pipeline products and treatment. As per the findings of the research, in the U.S., in 2011, hematological malignancies accounted for around 9% of newly diagnosed malignancies. Excluding Hodgkin’s lymphoma and acute lymphocytic leukemia, all other types of malignancies are associated with aging. Thus, the growing aging population is the key factor driving the hematological cancers market. Over the past decade, there have been many changes in the treatment of hematological malignancies. Rituxan and Gleevec are credited as two of the most successful drugs available in the market to treat hematological cancers. 

Click here to get more info with TOC in a PDF Format: http://www.researchmoz.us/enquiry.php?type=S&repid=751801

In 1997, Rituxan was approved to be used for treating various types of hematological cancers, including non-Hodgkin lymphoma. This is a prominent example of the robust pipeline of hematological cancer treatments and therapies bearing fruit. The report predicts that the increasing licensing deals, pipeline projects, and co-development deals will propel the hematological cancers market. Co-development deals and licensing deals are studied based on region, stage of development, and molecule type. As per the reports, since 2006, there have been around 238 co-development deals and 284 licensing deals related to hematological cancer products. 

The research lists leading players introducing new treatments and therapies for hematological cancers. At present, the hematological cancers market is highly competitive, with many pipeline products ready to be launched. Increasing government funding and the growing investments by leading companies for the discovery of new treatments will create new opportunities, predict the report’s authors. Innovations in treatments and therapies for treating hematological cancers will help leading players maintain their dominance through the forecast period. The assessment of pipeline products is done by considering the molecule type, therapeutic target, and phase of cancer. 

To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on sales@researchmoz.us